Proteomics-based identification of spontaneous regression-associated proteins in neuroblastoma.
BACKGROUND
Spontaneous regression is usually found in stage 4s neuroblastoma, whereas the elucidation of the underlying molecular mechanism(s) is still limited.


OBJECTIVE
Our study aims to investigate the pathogenesis of spontaneous regression at the protein level.


METHODS
Differential expression of proteins in stage 4s neuroblastoma tissue, in stage 4 neuroblastoma tissue, and in normal adrenal tissue was investigated by use of 2-dimensional difference gel electrophoresis (2D-DIGE).


RESULTS
Twenty-four protein spots were found to have significant changes among the different tissues, in which 16 proteins were identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Among these proteins, 7 proteins (RhoGDP-dissociation inhibitor 1, phosphatidylethanolamine-binding protein, prohibitin, etc) were up-regulated and 2 proteins (F-actin capping protein 1 subunit and aldose reductase) were down-regulated in stage 4s neuroblastoma compared with stage 4 neuroblastoma. The differential expression of selected candidate protein (RhoGDP-dissociation inhibitor 1 and CAPZA1) was further validated by western blotting.


CONCLUSIONS
Some proteins are differentially expressed between stage 4s and stage 4 neuroblastoma tissue, including those associated with differentiation and proliferation as well as apoptosis. RhoGDP-dissociation inhibitor 1 is highly expressed in stage 4s neuroblastoma tissue, whereas CAPZA1 is down-regulated.
Department of Pediatrics, Chinese PLA General Hospital, Beijing 100853, China.
Fang
F
Yu
Xiudan
X
Zhu
Chen
C
Feng
Tianyou
T
Wang
Qin
Q
Hong
Zhoulu
Z
Liu
Suoqin
S
Tang
D000310:Adrenal Gland Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology / Q000601:surgery; D000311:Adrenal Glands / Q000737:chemistry; D000315:Adrenalectomy; D017209:Apoptosis; D015153:Blotting, Western; D019046:Bone Marrow Neoplasms / Q000378:metabolism / Q000556:secondary; D051347:CapZ Actin Capping Protein / Q000032:analysis; D015180:Electrophoresis, Gel, Two-Dimensional; D015972:Gene Expression Regulation, Neoplastic; D020730:Guanine Nucleotide Dissociation Inhibitors / Q000032:analysis; D006801:Humans; D007223:Infant; D008113:Liver Neoplasms / Q000378:metabolism / Q000556:secondary; D009363:Neoplasm Proteins / Q000032:analysis*; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology / Q000556:secondary / Q000601:surgery; D011379:Prognosis; D040901:Proteomics; D012075:Remission, Spontaneous; D012878:Skin Neoplasms / Q000378:metabolism / Q000556:secondary; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D062947:rho-Specific Guanine Nucleotide Dissociation Inhibitors
C495842:CAPZA1 protein, human; D051347:CapZ Actin Capping Protein; D020730:Guanine Nucleotide Dissociation Inhibitors; D009363:Neoplasm Proteins; D062947:rho-Specific Guanine Nucleotide Dissociation Inhibitors